BACKGROUND: The application of Aldara(®) cream containing 5% imiquimod stimulates Toll-like receptor 7/8 on plasmacytoid dendritic cells, thereby producing a potent immunomodulatory effect. This has been reported to trigger psoriasis. OBJECTIVES: To establish a human model of Aldara-induced psoriasis-like skin inflammation in patients with psoriasis. METHODS: Nonlesional psoriatic skin of 13 patients was treated with Aldara for 2 or 7 days. The skin was evaluated clinically and histologically on days 2, 4 and 7. Cytokine expression in Aldara-treated, lesional and nonlesional psoriatic skin was compared using reverse-transcription quantitative polymerase chain reaction. RESULTS: Nine of the 10 patients receiving application of Aldara under occlusion for 2 days developed redness, induration and scaling. Histological analysis revealed focal parakeratosis, acanthosis and perivascular mononuclear infiltration. On days 4 and 7 both clinical and histological signs of inflammation subsided. Two of the three patients treated with Aldara for 7 days developed erosions leading to psoriasis on day 21. Cytokine markers of activation of the innate immune system [interferon-α, interferon regulatory factor-7 and interleukin (IL)-1β] were equally expressed in lesional and Aldara-treated skin (n = 6). IL-6 and tumour necrosis factor-α were preferentially expressed in Aldara-treated skin. Adaptive immune system activation occurred only partially: IL-23p19 and IL-22 were similarly overexpressed in Aldara-treated and lesional psoriatic skin, but IL-17A and IL-12p40 were significantly underexpressed in Aldara-treated skin compared with lesional psoriatic skin. IL-10 was significantly overexpressed in Aldara-treated skin. CONCLUSIONS: We were able to induce psoriasis-like skin inflammation although typical psoriasis did not develop, possibly due to incomplete adaptive immune system recruitment and the powerful stimulation of IL-10 counter-regulation.
BACKGROUND: The application of Aldara(®) cream containing 5% imiquimod stimulates Toll-like receptor 7/8 on plasmacytoid dendritic cells, thereby producing a potent immunomodulatory effect. This has been reported to trigger psoriasis. OBJECTIVES: To establish a human model of Aldara-induced psoriasis-like skin inflammation in patients with psoriasis. METHODS: Nonlesional psoriatic skin of 13 patients was treated with Aldara for 2 or 7 days. The skin was evaluated clinically and histologically on days 2, 4 and 7. Cytokine expression in Aldara-treated, lesional and nonlesional psoriatic skin was compared using reverse-transcription quantitative polymerase chain reaction. RESULTS: Nine of the 10 patients receiving application of Aldara under occlusion for 2 days developed redness, induration and scaling. Histological analysis revealed focal parakeratosis, acanthosis and perivascular mononuclear infiltration. On days 4 and 7 both clinical and histological signs of inflammation subsided. Two of the three patients treated with Aldara for 7 days developed erosions leading to psoriasis on day 21. Cytokine markers of activation of the innate immune system [interferon-α, interferon regulatory factor-7 and interleukin (IL)-1β] were equally expressed in lesional and Aldara-treated skin (n = 6). IL-6 and tumour necrosis factor-α were preferentially expressed in Aldara-treated skin. Adaptive immune system activation occurred only partially: IL-23p19 and IL-22 were similarly overexpressed in Aldara-treated and lesional psoriatic skin, but IL-17A and IL-12p40 were significantly underexpressed in Aldara-treated skin compared with lesional psoriatic skin. IL-10 was significantly overexpressed in Aldara-treated skin. CONCLUSIONS: We were able to induce psoriasis-like skin inflammation although typical psoriasis did not develop, possibly due to incomplete adaptive immune system recruitment and the powerful stimulation of IL-10 counter-regulation.
Authors: A Patidar; S Selvaraj; P Chauhan; C A Guzman; T Ebensen; A Sarkar; D Chattopadhyay; B Saha Journal: Clin Exp Immunol Date: 2020-06-26 Impact factor: 4.330
Authors: Joselin D Tacastacas; Patricia Oyetakin-White; David C Soler; Andrew Young; Sarah Groft; Kord Honda; Kevin D Cooper; Thomas S McCormick Journal: Photodermatol Photoimmunol Photomed Date: 2017-04-20 Impact factor: 3.135
Authors: Marcel Oliver Schmidt; Khalid Ammar Garman; Yong Gu Lee; Chong Zuo; Patrick James Beck; Mingjun Tan; Juan Antonio Aguilar-Pimentel; Markus Ollert; Carsten Schmidt-Weber; Helmut Fuchs; Valerie Gailus-Durner; Martin Hrabe de Angelis; Elena Tassi; Anna Tate Riegel; Anton Wellstein Journal: J Invest Dermatol Date: 2017-08-31 Impact factor: 8.551
Authors: Mårten C G Winge; Bungo Ohyama; Clara N Dey; Lisa M Boxer; Wei Li; Nazanin Ehsani-Chimeh; Allison K Truong; Diane Wu; April W Armstrong; Teruhiko Makino; Matthew Davidson; Daniela Starcevic; Andreas Kislat; Ngon T Nguyen; Takashi Hashimoto; Bernard Homey; Paul A Khavari; Maria Bradley; Elizabeth A Waterman; M Peter Marinkovich Journal: J Clin Invest Date: 2016-06-13 Impact factor: 14.808
Authors: Di Yan; Johann E Gudjonsson; Stephanie Le; Emanual Maverakis; Olesya Plazyo; Christopher Ritchlin; Jose U Scher; Roopesh Singh; Nicole L Ward; Stacie Bell; Wilson Liao Journal: J Invest Dermatol Date: 2021-07-22 Impact factor: 8.551